1. Home
  2. JQC vs DRUG Comparison

JQC vs DRUG Comparison

Compare JQC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

JQC

Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

HOLD

Current Price

$5.06

Market Cap

753.9M

Sector

Finance

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$77.40

Market Cap

856.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JQC
DRUG
Founded
2003
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
753.9M
856.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JQC
DRUG
Price
$5.06
$77.40
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$106.75
AVG Volume (30 Days)
714.6K
123.3K
Earning Date
01-01-0001
02-10-2026
Dividend Yield
11.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.82
$23.18
52 Week High
$5.65
$123.75

Technical Indicators

Market Signals
Indicator
JQC
DRUG
Relative Strength Index (RSI) 42.15 51.49
Support Level $5.02 $73.74
Resistance Level $5.14 $78.34
Average True Range (ATR) 0.04 4.81
MACD -0.01 -0.08
Stochastic Oscillator 10.00 59.14

Price Performance

Historical Comparison
JQC
DRUG

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: